Physician profile
David E Perloff
NPI 1548221237
$384,381.82
in general payments reported to CMS, 2019-2025
32 companies · $9,403 in 2025
The $9,403 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144K · 2020: $32K · 2021: $79K · 2022: $53K · 2023: $42K · 2024: $26K · 2025: $9,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Food and Beverage: $4,178 · Travel and Lodging: $4,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,255.50 |
| Food and Beverage | $4,178.44 |
| Travel and Lodging | $4,069.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $98,122.24 | 2020-2025 | Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $85,195.47 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73,107.75 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $37,648.79 | 2019-2024 | Jardiance |
| Amgen INC. | $35,139.26 | 2021-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $26,521.71 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $10,285.70 | 2019 | |
| Merck Sharp & Dohme LLC | $7,043.81 | 2021-2025 | Verquvo |
| Pfizer INC. | $5,626.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,713.44 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $901.01 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Resonate El Icd Vr |
| E.R. Squibb & Sons, L.L.C. | $698.94 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $413.18 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $320.60 | 2021-2023 | |
| Atricure, INC. | $245.00 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $228.03 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $146.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $142.26 | 2020-2024 | Xarelto |
| Edwards Lifesciences Corporation | $121.68 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $119.30 | 2020-2023 | |
| Novo Nordisk INC | $113.62 | 2021-2024 | Ozempic, Wegovy |
| Cardiofocus, INC. | $110.05 | 2020 | |
| Heartflow, INC. | $104.07 | 2023-2025 | Ffrct |
| Biotronik INC. | $91.07 | 2022-2025 | Biomonitor |
| Kiniksa Pharmaceuticals International, Plc | $60.22 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $42.51 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $24.67 | 2021 | |
| Abiomed | $22.80 | 2025 | |
| Inspire Medical Systems, INC. | $20.72 | 2025 | Inspire |
| Medtronic, INC. | $19.42 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.03 | 2021 | |
| Baxter Healthcare | $14.63 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Perloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.